Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Li, Weidong ^a   Chen, Cihui ^b   Saud, Shakir M ^c   Geng, Liang ^d   Zhang, Ge ^a   Liu, Rui ^a   Hua, Baojin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cyclophosphamide; Epithelial mesenchymal transition; Fei Liu Ping ointment; Inflammation; Invasion; Lung cancer; Nuclear factor kappa light chain enhancer of activated B cells

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; CYCLOPHOSPHAMIDE; FEI LIU PING; GELATINASE A; GELATINASE B; HERBACEOUS AGENT; INTERLEUKIN 1BETA; NERVE CELL ADHESION MOLECULE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; FEI-LIU-PING; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; OINTMENT;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL LINE; CELL GROWTH; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LEWIS CARCINOMA; LUNG CANCER; METASTASIS; MOUSE; NONHUMAN; OINTMENT; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; MACROPHAGE; MALE; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUNG NEOPLASMS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NF-KAPPA B; OINTMENTS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901602208     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-153     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10-30. 10.3322/canjclin.55.1.10, 15661684.
2. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006, 51(2):181-191. 10.1016/j.lungcan.2005.10.003, 16324768.
3. Brekken RA, Thorpe PE. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2001, 21(6B):4221-4229.
4. Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med 2012, 12:112. 10.1186/1472-6882-12-112, 3502343, 22853619.
5. Guo H, Liu JX, Xu L, Madebo T, Baak JP. Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther 2011, 10(2):127-137. 10.1177/1534735410387599, 21147812.
6. Wan C, You S, Quan P, Song Y, Liu T, Lu J, Zheng P. Development and validation of the quality-of-life assessment system for lung cancer based on traditional Chinese medicine. Evid Based Complement Altern Med 2012, 2012:945910.
7. Wong R, Sagar CM, Sagar SM. Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 2001, 27(4):235-246. 10.1053/ctrv.2001.0227, 11545543.
8. Yang D, Tian G. Review of experimental study on treatment of lung cancer with traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi 2009, 34(18):2405-2409.
9. Zhang P, Piao B, Sun G. Influence of feiliuping No. 2 on platelet surface glycoprotein expression in mid-late stage lung cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000, 20(1):31-33.
10. Zheng HG, Piao BK, Hua BJ. Effect of feiliuping ointment and its disassembled prescriptions on dendritic cell of mice with transplanted Lewis lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010, 30(12):1288-1291.
11. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339(6117):286-291. 10.1126/science.1232227, 3591506, 23329041.
12. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013, 33(Suppl 1):S79-84.
13. Bochu W, Liancai Z, Qi C. Primary study on the application of serum pharmacology in Chinese traditional medicine. Colloids Surf B: Biointerfaces 2005, 43(3-4):194-197.
14. Cao Y, Zhang D, Zheng G, Zhang J. Study on effect of drug concentration of "Bushen huayu jiedu fang" drug serum on drug-resistance lung cancer cells with serum pharmacology. Zhong Yao Cai 2003, 26(4):263-265.
15. Plezia PM, Alberts DS, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA, Meyskens FL. The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Prev Med 1989, 18(5):680-687. 10.1016/0091-7435(89)90039-X, 2694162.
16. Walther H, Meyer FP, Quednow B, Leuschner U, Kohler E, Horenburg I. Dosage monitoring through measurement of serum level-a task of clinical pharmacology. Int J Clin Pharmacol Biopharm 1978, 16(8):387-390.
17. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97(11):2919-2925. 10.1002/cncr.11382, 12767108.
18. Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Cleeland CS. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004, 11(5):279-292. 10.1159/000079408, 15316238.
19. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav Immun 2001, 15(1):7-24. 10.1006/brbi.2000.0613, 11259077.
20. Rube CE, Wilfert F, Uthe D, Konig J, Liu L, Schuck A, Willich N, Remberger K, Rube C. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol 2004, 72(2):231-241. 10.1016/j.radonc.2004.05.004, 15297141.
21. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2(4):301-310. 10.1038/nrc780, 12001991.
22. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2(10):725-734. 10.1038/nri910, 12360211.
23. Birchmeier W, Birchmeier C. Epithelial-mesenchymal transitions in development and tumor progression. EXS 1995, 74:1-15.
24. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17(5):548-558. 10.1016/j.ceb.2005.08.001, 16098727.
25. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7(2):131-142. 10.1038/nrm1835, 16493418.
26. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25(1):9-34. 10.1007/s10555-006-7886-9, 16680569.
27. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284(5751):67-68. 10.1038/284067a0, 6243750.
28. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25(8):1543-1549. 10.1093/carcin/bgh146, 15044327.
29. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175(2):1197-1205. 10.4049/jimmunol.175.2.1197, 16002723.
30. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6(3):203-208. 10.1016/j.ccr.2004.09.003, 15380510.
31. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. in Cancer Res 2009, 15(2):425-430.
32. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A 2007, 104(47):18514-18519. 10.1073/pnas.0705316104, 2141808, 18000061.
33. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 2008, 6(3):364-371. 10.1158/1541-7786.MCR-07-0309, 18337446.
34. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462(7269):104-107. 10.1038/nature08462, 2780341, 19847165.
35. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010, 17(1):89-97. 10.1016/j.ccr.2009.12.008, 2818776, 20129250.
36. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3(1):17-26. 10.1038/nrd1279, 14708018.
37. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16(6):1053-1068. 10.1038/sj.leu.2402482, 12040437.
38. Zhang Y, Chen F. Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res 2004, 64(6):1902-1905. 10.1158/0008-5472.CAN-03-3361, 15026320.
39. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3(3):221-227. 10.1038/ni0302-221, 11875461.
40. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 2012, 72(5):1290-1300. 10.1158/0008-5472.CAN-11-3123, 3350107, 22253230.